<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04666298</url>
  </required_header>
  <id_info>
    <org_study_id>CKJX839A11201</org_study_id>
    <nct_id>NCT04666298</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C</brief_title>
  <official_title>A Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Effect of Different Doses of Inclisiran Given as Subcutaneous Injections in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the efficacy and safety of inclisiran in Japanese&#xD;
      participants with an increased LDL-C concentrations. The study also evaluates the&#xD;
      pharmacokinetics of inclisiran in a subset of Japanese participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 29, 2021</start_date>
  <completion_date type="Anticipated">December 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 23, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 180</measure>
    <time_frame>Baseline, Day 180</time_frame>
    <description>Superiority of inclisiran treatment at different dose levels (100 mg, 200 mg, and 300 mg) to placebo on LDL-C levels at Day 180</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change in proprotein convertase subtilisin/kexin type 9(PCSK9) levels from baseline to Days 14, 30, 60, 90, 104, 120, 150, and 180</measure>
    <time_frame>Baseline, Days 14, 30, 60, 90, 104, 120, 150, and 180</time_frame>
    <description>The effect of inclisiran until Day 180 on PCSK9 levels over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in LDL-C from baseline to Days 14, 30, 60, 90, 104, 120, and 150</measure>
    <time_frame>Baseline, Days 14, 30, 60, 90, 104, 120, and 150</time_frame>
    <description>The effect of inclisiran until Day 180 on LDL-C levels over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in LDL-C from baseline to Day 180</measure>
    <time_frame>Baseline, Days 14, 30, 60, 90, 104, 120, 150, and 180</time_frame>
    <description>The effect of inclisiran until Day 180 on LDL-C levels over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants in each group with LDL-C greater than 80% of the baseline value at Day 180</measure>
    <time_frame>Baseline, Day 180</time_frame>
    <description>The effect of inclisiran until Day 180 on LDL-C levels over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants in each group with greater or equal to 50% LDL-C reduction from baseline at Days 14, 30, 60, 90, 104, 120, 150, and 180</measure>
    <time_frame>Baseline, Days 14, 30, 60, 90, 104, 120, 150, and 180</time_frame>
    <description>The effect of inclisiran until Day 180 on LDL-C levels over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in other lipids, lipoproteins, apolipoproteins from baseline to Days 14, 30, 60, 90, 104, 120, 150, and 180</measure>
    <time_frame>Baseline, Days 14, 30, 60, 90, 104, 120, 150, and 180</time_frame>
    <description>The effect of inclisiran until Day 180 on Other lipids, lipoproteins, apolipoproteins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants in each group who attain lipid control target pre-specified by Japan Atherosclerosis Society(JAS) 2017 guidelines for their level of cardiovascular risk at Day 180</measure>
    <time_frame>Day 180</time_frame>
    <description>The effect of inclisiran until Day 180 on the proportion of participants achieving lipid control target pre-specified by Japan Atherosclerosis Society(JAS) 2017 guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual responsiveness defined as: Number of participants reaching on treatment LDL-C levels of &lt;25 mg/dL, &lt;50 mg/dL, &lt;70 mg/dL, and &lt;100 mg/dL at Days 14, 30, 60, 90, 104, 120, 150, and 180</measure>
    <time_frame>Days 14, 30, 60, 90, 104, 120, 150, and 180</time_frame>
    <description>The effect of inclisiran until Day 180 on Individual responsiveness to different doses</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">312</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Heterozygous Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>300 mg inclisiran sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg inclisiran sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg inclisiran sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inclisiran sodium</intervention_name>
    <description>Subcutaneously injected on Day 1, 90 and 270.</description>
    <arm_group_label>100 mg inclisiran sodium</arm_group_label>
    <arm_group_label>200 mg inclisiran sodium</arm_group_label>
    <arm_group_label>300 mg inclisiran sodium</arm_group_label>
    <other_name>KJX839</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneously injected on Day 1, 90, and 270.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>KJX839 placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants with history of CAD or participants categorized in 'high risk' by Japan&#xD;
             Atherosclerosis Society (JAS) 2017 guidelines or participants with heterozygous&#xD;
             familial hypercholesterolemia (HeFH)&#xD;
&#xD;
          -  As per the JAS 2017 guideline, participants not meeting the LDL-C management targets.&#xD;
&#xD;
          -  Participants on statins should be receiving a maximally tolerated dose.&#xD;
&#xD;
          -  Participants not receiving statins must have documented evidence of intolerance to at&#xD;
             least one statin.&#xD;
&#xD;
          -  The lipid-lowering therapy should have remained stable for â‰¥ 30 days before screening&#xD;
             with no planned medication/ dose change until Day 180&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants diagnosed with homozygous familial hypercholesterolemia (HoFH).&#xD;
&#xD;
          -  Treatment (within 90 days of screening) with monoclonal antibodies directed towards&#xD;
             PCSK9.&#xD;
&#xD;
          -  New York Heart Association (NYHA) class IV heart failure or last known left&#xD;
             ventricular ejection fraction &lt;25%.&#xD;
&#xD;
          -  Cardiac arrhythmia within 3 months prior to randomization that is not controlled by&#xD;
             medication or via ablation.&#xD;
&#xD;
          -  Uncontrolled hypertension: systolic blood pressure &gt;160 mmHg or diastolic blood&#xD;
             pressure &gt;100 mmHg prior to randomization despite antihypertensive therapy.&#xD;
&#xD;
          -  Active liver disease defined as any known current infectious, neoplastic, or metabolic&#xD;
             pathology of the liver or unexplained elevations in alanine aminotransferase (ALT),&#xD;
             aspartate aminotransferase (AST), &gt;3x the upper limit of normal (ULN), or total&#xD;
             bilirubin &gt;2x ULN at screening.&#xD;
&#xD;
          -  Severe concomitant non-cardiovascular disease that carries the risk of reducing life&#xD;
             expectancy to less than 2 years.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Matsudo city</city>
        <state>Chiba</state>
        <zip>271 0077</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Itoshima</city>
        <state>Fukuoka</state>
        <zip>819-1104</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitakyushu-city</city>
        <state>Fukuoka</state>
        <zip>806-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>800-0057</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>804-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>805-8508</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nakagawa</city>
        <state>Fukuoka</state>
        <zip>811-1244</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo-city</city>
        <state>Hokkaido</state>
        <zip>006-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>062-8618</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sashima-gun</city>
        <state>Ibaraki</state>
        <zip>306-0433</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki</state>
        <zip>300-0028</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kahoku-gun</city>
        <state>Ishikawa</state>
        <zip>920-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kanazawa-city</city>
        <state>Ishikawa</state>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920 8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Komatsu</city>
        <state>Ishikawa</state>
        <zip>923-0961</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Takamatsu city</city>
        <state>Kagawa</state>
        <zip>760 8557</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fujisawa-city</city>
        <state>Kanagawa</state>
        <zip>251-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kawasaki-city</city>
        <state>Kanagawa</state>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuse</city>
        <state>Kyoto</state>
        <zip>613-0034</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>983-0039</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Omura</city>
        <state>Nagasaki</state>
        <zip>856-8562</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izumisano-city</city>
        <state>Osaka</state>
        <zip>598-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Matsubara-city</city>
        <state>Osaka</state>
        <zip>580-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka city</city>
        <state>Osaka</state>
        <zip>530 0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka-city</city>
        <state>Osaka</state>
        <zip>540-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka-city</city>
        <state>Osaka</state>
        <zip>543-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suita-city</city>
        <state>Osaka</state>
        <zip>565-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>564-8565</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Iruma-gun</city>
        <state>Saitama</state>
        <zip>350-0495</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sayama-city</city>
        <state>Saitama</state>
        <zip>350-1305</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiyoda</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103-0028</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nerima-ku</city>
        <state>Tokyo</state>
        <zip>176-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>142-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku ku</city>
        <state>Tokyo</state>
        <zip>160-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuoh-ku</city>
        <zip>104-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gifu</city>
        <zip>500-8384</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyoto</city>
        <zip>612-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oita</city>
        <zip>870-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saga</city>
        <zip>840-8571</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 7, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inclisiran, siRNA, dyslipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

